
Oct 16, 2026
Iambic CEO on taking an AI drug company public
Iambic Therapeutics is navigating the volatile waters of the AI-driven drug development market with a recent IPO that aims to distinguish itself from other AI-focused companies that have struggled publicly.The stock performance of AI drug developers has been mixed, with companies like Exscientia and Recursion Pharmaceuticals experiencing significant declines since their public offerings. In contrast, Iambic, which launched in 2019, has successfully raised substantial funding, including $150 mill




